O r i g i n a l A r tic le
I NTRO D U C TIO N
Renal transplant rejection involves both immunological (alloantigen-dependent) and non-immunological (alloantigenindependent) factors. Acute rejection (AR), which remains a major risk factor for the development of chronic rejection, (1) involves a network of cytokines, growth factors and costimulatory molecules. (2) Several cytokines such as interleukin 2, 5, 6 and 12 (IL-2, IL-5, IL-6, and IL-12, respectively), tumour necrosis factor alpha (TNF-α) and interferon gamma are known to play important roles in the activation of immune responses that involve cytotoxic T-lymphocytes, natural killer (NK) cells and monocytes. (3) Cytokines play an important role in allograft survival. (4) A pleiotropic, multifunctional and proinflammatory cytokine with a molecular weight of 26 kD, IL-6 modulates both local and systemic immunity. (5, 6) Overproduction of leads to the deposition of extracellular matrix proteins, development of inflammatory lesions and synthesis of acute phase proteins. (6) (7) (8) While TNF-α, which is also a cytokine like IL-6, is predominantly produced by macrophages, it can also be produced by monocytes and NK cells. TNF-α plays a central role in immune response. Studies have shown that serum TNF-α levels are increased in renal transplant recipients (RTRs) during rejection. (9) (10) (11) Vascular permeability is enhanced by TNF-α, thus leading to the infiltration of the graft by proinflammatory granulocytes. (12) IL-6 and TNF-α can alter lipid metabolism and produce hyperlipidaemia, leading to atherosclerotic processes. (13, 14) A progressive rise in serum creatinine (SCr), together with proteinuria, hypertension and a decline in glomerular filtration rate, are features characteristic of chronic allograft injury (CAI). (15) Dyslipidaemia is an important non-immunological factor associated with the progression of kidney disease in transplant patients. (16) TNF-α and IL-6 are known to be significant predictors of the severity of coronary artery disease (CAD) in heart allograft recipients. (17) The findings of these studies were considered in the design of our study, which aimed to investigate the association of the cytokines, serum IL-6 and TNF-α, as markers of allograft rejection in RTRs and the association of these immunological factors with nonimmunological factors such as age, SCr, creatinine clearance (CrCl) and dyslipidaemia.
Evaluation of serum interleukin 6 and tumour necrosis factor alpha levels, and their association with various non-immunological parameters in renal transplant recipients
M e Th O Ds
In a three-year period from January 2008 to December 2010, a total of 180 subjects were enrolled in this study. cholesterol (TC), high-density lipoprotein (HDL) and lowdensity lipoprotein (LDL) levels were assayed using standard methodology. CrCl was calculated using the Cockroft-Gault equation. (19) All biopsies were reviewed by a renal pathologist, and rejections that were confirmed on biopsy were classified according to the Banff '05 criteria. 
ResUlTs
Age, taken as a demographic parameter, showed no significant difference among the various groups (Table I ). In the RTRs, the metabolic parameters SCr and CrCl were significantly raised and lowered, respectively, when compared to the control group.
Although the SCr of the TS group was within normal limits, it was still slightly higher than that of the control group. SCr was highest in the TR group, with significantly higher values in patients with CAI than those with AR. CrCl was significantly lowered in the RTRs when compared to the control group.
Although CrCl in the TS and control groups did not show significant variation, the variation seen was greater than that in the TR group. Within the TR group, CrCl was significantly decreased in patients with CAI when compared to those with AR.
The level of the two cytokines (i.e. serum IL-6 and serum TNF-α) evaluated in this study were higher in the RTRs than the control group. The levels of both serum IL-6 and serum CrCl: creatinine clearance; HDL: high-density lipoprotein; IL-6: interleukin 6; LDL: low-density lipoprotein; NS: not significant; SCr: serum creatinine; SD: standard deviation; TC: total cholesterol; TNF-α: tumour necrosis factor alpha TNF-α were significantly elevated in patients from the TR group when compared to those from the TS and control groups.
However, when the cytokine levels were compared between the TS and control groups, only serum TNF-α was significantly elevated in the TS group. When the difference between the cytokine levels of patients with AR and those with CAI were analysed, both IL-6 and TNF-α were found to be higher in patients with CAI (Table I ).
The lipid profile parameters evaluated in our study were TC, HDL and LDL. The levels of all these parameters were lower in the RTRs than in the control group. Similar trends were observed when the RTRs were split into TS and TR groups and the respective group's lipid profile parameters were compared with the control group. When compared to the TS and control groups, the TR group had a significantly lower HDL level, while both TC and LDL levels were within normal limits.
There was a greater reduction in HDL level in patients with CAI than in those with AR, although the difference was not significant (Table I ).
In the RTRs, univariate analysis showed that serum IL-6
and TNF-α levels correlated significantly with metabolic parameters and dyslipidaemia (Table II) (Table III) .
D I sCU s s IO N
Renal allograft rejection involves a network of cytokines, growth factors and co-stimulatory molecules. (2) Several cytokines play an important role in the activation of immune responses. Our study showed a significant increase in the level of cytokines in RTRs, with both serum IL-6 and TNF-α levels being significantly higher than that in the control group. In our study, the mean serum IL-6 level in the control group was 7.51 ± 2.63 pg/mL. Similarly, studies by Waiser et al (5) and Kamimura et al (21) found slightly lower levels of IL-6 in controls, with reported mean values of 3.5 ± 1.1 pg/mL and 0.24 ± 0.05 pg/mL, respectively. We also found that the elevation of serum TNF-α was significantly higher in both the TS and TR groups. This finding is consistent with other studies, which reported significantly lower serum TNF-α levels in controls than in transplant recipients experiencing organ rejection. (9, 10, 22) We postulate that injury to the endothelium might trigger the release of IL-6 in RTRs. A German study reported that when compared to controls, both the levels of serum IL-6 in patients undergoing episodes of rejection and the levels of IL-6 in biopsy tissues of kidneys undergoing rejection were elevated. (5) This increase in IL-6 could be the result of increased activation of nuclear factor-kappa B, which is an inducible transplantation factor essential for the activation of several important inflammatory cytokine genes such as the IL-6 and IL-8 genes. (23, 24) Lipid abnormalities are very common in patients undergoing rejection, and hyperlipidaemia or dyslipidaemia is an important non-immunological risk factor for the rejection of grafts. High cholesterol, high LDL and elevated triglycerides have been reported in RTRs, before and after transplant. (25) (26) (27) (28) The elevation of cytokines and lipids indicates that RTRs are not only characterised by persistent immune alloactivation, but also by lipid metabolism disorders. In our study, the serum IL-6, TNF-α, TC and LDL levels of patients with CAI were significantly higher than those in patients with AR.
Lipid levels are modulated by various mechanisms. (29) Reports suggest that oxidised LDL may lead to increased production of proinflammatory cytokines and chemokines by macrophages and the endothelium. (30, 31) A study by Gullestad et al on the role of IL-6 in heart allograft CAD reported an increase in IL-6 and LDL in patients with transplant CAD. (22) In that study, the authors also showed that heart transplant patients with coronary dysfunction leading to heart allograft rejection have lower HDL levels, and higher TC and LDL levels than controls and patients with stable allografts. These findings are similar to that of our study on RTRs. We also found lower HDL levels, and higher TC and LDL levels in the TR group when compared to the TS group.
Gullestad et al further reported an inverse correlation between HDL level and the levels of TNF-α and IL-6 in their cohort of patients with or without allograft rejection, (22) which is similar to what was observed in our patients with or without transplant rejection.
A complex interrelation exists between cytokines and lipids. Studies have suggested that IL-6 may cause an increase in circulating lipid levels, probably through a decrease in peripheral lipoprotein lipase. (32, 33) In our study, HDL levels showed negative significant correlation with IL-6 and TNF-α, and were higher in the control and TS groups than in the TR group. During graft rejection, endothelium activation leads to the expression of adhesion molecules such as intercellular adhesion molecule 1, vascular cell adhesion molecule 1 and E-selectin. (34, 35) HDL disrupts the sphingosine kinase signalling pathway, resulting in the inhibition of the endothelium, which protects against the formation of atherosclerotic plaques in the blood vessels of the graft. (36) Endothelium-derived cytokines play an important role in several diseases, including atherosclerosis, graft rejection, asthma, vasculitis and sepsis. (37) Chen et al suggested that TNF-α might be a potent regulator of lipid metabolism. (38) Kario et al showed that a close relationship between high lipoprotein levels and IL-6 is present in haemodialysis patients. (39) IL-6 is responsible for increased hepatic production of fatty acids, triglycerides and cholesterol. (40) Our finding that hypercholesterolaemia is an important risk factor for renal graft rejection is in agreement with the study by Swan. (41) The elevation of serum IL-6 and TNF-α levels in
RTRs therefore appears to be associated with dyslipidaemia.
In our study, we obtained a negative significant correlation between IL-6 and TNF-α levels, and CrCl, thus indicating that these cytokines are associated with declining renal function.
Similar results were also reported by other studies on patients with renal transplant rejection and chronic renal failure. (42, 43) In conclusion, immunological factors, as well as nonimmunological factors such as SCr, CrCl and dyslipidaemia, play important roles in renal graft dysfunction and the pathogenesis of graft rejection.
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